Login to Your Account

Millennium Sells Integrilin Rights In U.S. To Schering

By Karen Pihl-Carey

Tuesday, July 26, 2005
Millennium Pharmaceuticals Inc. restructured its collaboration for Integrilin, granting exclusive U.S. development and commercialization rights to Schering-Plough Corp. and trading its profit-sharing arrangement for a significant royalty and up to $85.5 million in payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription